Cerevel Therapeutics Advances in Merger Amid FTC Review
Company Announcements

Cerevel Therapeutics Advances in Merger Amid FTC Review

Cerevel Therapeutics Holdings (CERE) has released an update.

Cerevel Therapeutics Holdings, Inc. successfully held a special stockholders’ meeting to vote on a merger with AbbVie Inc., receiving overwhelming approval with a high stockholder turnout. Additionally, the company is addressing a request from the FTC for more information, which extends the antitrust review period. Despite this, Cerevel remains optimistic about completing the merger by mid-2024, pending regulatory approval and fulfillment of other conditions.

For further insights into CERE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCerevel Therapeutics’ Corporate Transformation and Market Delisting
TheFlyAbbVie completes acquisition of Cerevel Therapeutics
Carrie WilliamsCERE Upcoming Earnings Report: What to Expect?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App